News

The Novel Discovery by The University of British Columbia and SignalChem Lifesciences Corporation Has Been Published by the Prestigious Journal “Blood”

March 31, 2021
Continue Reading

The Novel Discovery by The University of British Columbia and SignalChem Lifesciences Corporation Has Been Published by the Prestigious Journal “Blood”

Key points:

· AXL activity is upregulated in acute myeloid leukemia (AML) stem/progenitor cells.

· A novel AXL inhibitor SLC-391 is developed with favorable pharmaceutical properties.

· AXL inhibition sensitizes AML cells to venetoclax, with strong synergistic effects via

AXL/BCL-2-mediated OXPHOS/signaling pathways.

VANCOUVER, BRITISH COLUMBIA – March 31, 2021 – SignalChem Lifesciences Corporation (“SLC”) is pleased to announce that a paper entitled “Targeting AXL Kinase Uniquely Sensitizes Therapy-Insensitive Leukemic Stem and Progenitor Cells to Venetoclax Treatment in Acute Myeloid Leukemia” has been published as First Edition by the journal “Blood” today. The research work described in this paper is the collaboration between University of British Columbia and SLC and it was supported by MITACS Accelerate program.

In this study, we demonstrated that a key GAS6/AXL axis is highly activated in AML patient cells, particularly in stem/progenitor cells. We developed a potent, selective AXL inhibitor that has favorable pharmaceutical properties and efficacy against preclinical patient-derived xenotransplantation (PDX) models of AML. Importantly, inhibition of AXL sensitized AML stem/progenitor cells to venetoclax treatment, with strong synergistic effects in vitro and in PDX models. Mechanistically, single-cell RNA-sequencing and functional validation studies uncovered that AXL inhibition or in combination with venetoclax potentially targets intrinsic metabolic vulnerabilities of AML stem/progenitor cells, which shows a distinct transcriptomic profile and inhibits mitochondrial oxidative phosphorylation. Inhibition of AXL or BCL-2 also differentially targets key signaling proteins to synergize in leukemic cell killing. These findings have direct translational impact on the treatment of AML and other cancers with high AXL activity.

“This new study has uncovered that AXL, one of key cancer drivers, is abnormally activated in blood cancer cells from AML patients, a difficult disease to treat. In this study we found that both genetic inhibition of AXL and the use of a highly selective AXL inhibitor SLC-391, in combination with a BCL-2 inhibitor (venetoclax) preferentially eliminate AML blast cells from drug-insensitive patients both in vitro and in preclinical PDX models, while not being toxic to healthy bone marrow cells. This new combination treatment approach may lead to more effective disease eradication, especially in patients at high risk of drug resistance and disease progression. Encouragingly, SLC-391 is currently being evaluated in a Phase I clinical trial in solid tumors, which opens a promising avenue for combination cancer therapies,” commented by Professor Xiaoyan Jiang in the Department of Medical Genetics of the University of British Columbia and Distinguished Scientist at BC Cancer, the senior author and the principal investigator of this paper. “We are very pleased with the recognition of this discovery by Professor Jiang’s lab in collaboration with SLC. We are going to pursue the clinical research in combination therapy of SLC-391 with a putative BCL-2 inhibitor in this AML patient population and hope that it will provide another valuable therapy to fight against this terrible disease,” said Mr. Jun Yan, President of SLC, “We have been working very hard to develop new anti-tumour therapies which provide superior advantages over the existing treatments.”

SLC-391 is clinical stage small molecule AXL inhibitor with good potency and selectivity with desirable pharmaceutical properties. It has good selectivity against other tyrosine kinases. The pharmacokinetic studies in rodents and dogs indicated that SLC-391 has high bioavailability with a simple suspension formulation (>50%). The in vivo studies demonstrated efficacy in different animal models including NSCLC, CML and AML models. Moreover, it has exhibited a strong synergistic effect in tumour growth inhibition in combination with erlotinib and paclitaxel in NSCLC xenograft models and demonstrated a strong synergistic effect in decreasing leukemia burden and enhancing survival of leukemic animals in a novel combination approach with BCL-2 inhibitor venetoclax in aggressive xenotransplant AML leukemic models and PDX models. In a CT-26 colon cancer syngeneic model, SLC-391 played a role in modulating both the innate and adaptive immune responses and demonstrated a synergistic effect in tumour growth inhibition and overall survival in combination with an anti-PD-1 antibody. In addition, SLC-391 promotes anti-tumour immunity through modulation of tumour-associated macrophage polarization. Currently, SLC-391 is under phase I safety clinical evaluations in multi-cancer centres in Canada and the dose expansion phase is anticipated to be complete by Q3/2021.

About SignalChem

SignalChem Lifesciences Corporation (“SLC”) is a multi-platform, clinical-stage, drug discovery and development company focusing on development of next generation of novel, small molecule kinase inhibitors as targeted therapy for the treatment of cancer. SLC has a strong small-molecule drug development pipeline. SLC is seeking strategic partners to aid in bringing our clinical-stage drug pipeline to the market. SignalChem Biotech Inc. (https://www.signalchem.com), a separate division from SignalChem Lifesciences, is a biotech company focused on the research, development and production of innovative and high-quality human recombinant cell signaling products. Throughout the years, SignalChem has capitalized on its core expertise in cellular signaling, molecular biology and protein biochemistry to generate more than 3,000 functional protein products.

SignalChem strives to support scientists in academia, pharma and biotech companies around the world by creating effective research tools to advance the basic research in life sciences and to facilitate the efforts in drug discovery and development. For more information, please visit https://www.signalchemlifesciences.com.

Forward-Looking Statements and Information

This release contains forward-looking statements that are not based on historical facts. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied. Readers are cautioned not to place undue reliance on such forward-looking statements.

Contact
Zaihui Zhang, PhD
CSO, VP R&D
SignalChem Lifesciences Corp.
+ 604 232 4600 ext. 114

SignalChem Enters a Clinical Trial Collaboration with Merck to Evaluate the Effect of SLC-391 in Combination with KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cance

March 23, 2021
Continue Reading

SignalChem Lifesciences, a clinical-stage company developing novel targeted therapies for oncology, announces a collaboration with Merck, known as MSD outside of the United States and Canada, through a subsidiary, to evaluate the combination of SLC-391, a selective AXL inhibitor developed by SignalChem, with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with advanced non-small cell lung cancer (NSCLC).

AXL, a member of the TAM family protein tyrosine kinases (Tyro3, AXL and Mer), plays a key role in cell survival, angiogenesis, metastasis and therapeutic resistance. SLC-391 is a clinical stage small molecule AXL inhibitor with high potency, selectivity and desirable pharmaceutical properties. SLC-391 disrupts cell division, inhibiting tumor growth and causing cancer cells to die.

Based on emerging evidence, a clinical investigation has been initiated to evaluate SLC-391 in combination with KEYTRUDA in the treatment of patients with advanced NSCLC.

SignalChem will conduct the study in multiple cancer centers in the US and Canada to evaluate the clinical outcome of combining SLC-391 and KEYTRUDA. The two companies plan to conduct the SKYLITE trial, a phase 2 study for patients with NSCLC.

The SKYLITE trial is a multi-centre, single arm, open-label, Phase 2 Study of SLC-391 in combination with KEYTRUDA in subjects with NSCLC. Subjects will receive daily doses of SLC-391 orally for 21-day cycles in combination with the commercially approved dose and schedule of KEYTRUDA. The SKYLITE trial will evaluate the safety and efficacy of the combination therapy, and includes the exploration of biomarkers relating to AXL signaling that may correlate with anti-tumour activity.

“We welcome the collaboration with Merck. We consider Merck’s clinical development expertise to be valuable and believe this relationship may contribute to the development of SLC-391 for the treatment of patients with advanced stage lung cancer. These patients experience aggressive tumors that are often difficult to treat. We hope this collaboration with Merck will lead to a new approach that addresses this important unmet need,” says Mr. Jun Yan, President, SignalChem Lifesciences. “We look forward to partnering with Merck as we aim to deliver new cancer treatments and advance SLC’s drug discovery platform. We at SLC are working hard to identify new anti-tumour, anti-metastatic, and anti-chemo-resistance therapies that provide meaningful alternatives to existing treatments.”

About Lung Cancer

Lung cancer, which forms in the tissues of the lungs, usually within cells lining the air passages, is the leading cause of cancer death worldwide. Each year, more people die of lung cancer than colon, breast and prostate cancers combined. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Survival rates over 5 years are very low. NSCLC is the most common type of lung cancer, accounting for 84% of all lung cancer diagnoses. Lung cancer makes up about 13% of all new cancer diagnoses and is the second most common cancer and the leading cause of cancer death for men and women. The overall 5-year survival rate for NSCLC is 24%, ranging from 61% for localized NSCLC to 6% for metastatic disease.

About SLC-391

SLC-391 is a potent, selective and orally bioavailable small molecule AXL inhibitor. Currently, phase I clinical trial is ongoing in Canada to evaluate the safety and tolerability of SLC-391 in cancer patients with solid tumour.

About SignalChem

SignalChem Lifesciences Corporation (“SLC”), headquartered in British Columbia, Canada, is a clinical-stage company developing novel targeted therapies for oncology. SLC has a strong small-molecule drug development pipeline (https://signalchemlifesciences.com/pipeline.php). Our novel targeted compounds are designed internally by a group of scientists with expertise and experience in kinase biology and drug discovery. SLC is seeking strategic partners to aid in bringing our clinical-stage drug pipeline to the market. SignalChem (https://www.signalchem.com), a separate division from SignalChem Lifesciences, is a biotech company focused on the research, development and production of innovative and high-quality human recombinant cell signaling products. Throughout the years, SignalChem has capitalized on its core expertise in cellular signaling, molecular biology and protein biochemistry to generate more than 2,000 functional protein products.

SignalChem strives to support scientists in academia, pharma and biotech companies around the world by creating effective research tools to advance the basic research in life sciences and to facilitate the efforts in drug discovery and development. For more information, please visit https://www.signalchemlifesciences.com.

Forward-Looking Statements and Information

This release contains forward-looking statements that are not based on historical facts. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied. Readers are cautioned not to place undue reliance on such forward-looking statements.

Contact:

Zaihui Zhang, PhD

CSO, VP R & D

SignalChem Lifesciences Corp.

+ 604 232 4600 ext. 114

SIGNALCHEM BIOTECH INC launches new IVD line of products

February 26, 2021
Continue Reading

SIGNALCHEM BIOTECH INC. LAUNCHES NEW IN VITRO DIAGNOSTICS LINE OF PRODUCTS FOR ALLERGENS

 

SignalChem, a global leader in cell signaling and protein engineering, has developed an extensive portfolio of bioallergens from various animal, plant, mold, and food sources following strict manufacturing processes and stringent quality control and assurance systems. These products are intended for in vitro diagnosis and research studies.

"We aim to provide high-quality recombinant allergens to the global scientific community to aid the development of kits/tests for better diagnosis of IgE mediated allergies and related therapeutic interventions."  states Jun Yan, President of the company.

These allergens are excellent candidates for use in in vitro studies of antigen presentation, T cell functions & research, IgE response, innate immune response, and can expedite the development of improved antibody detection kits, histamine assays, and allergy response related biological assays.

"Our goal is to manufacture allergen that can demonstrate high detection rate and low false positive in testing combined with excellent pricing and a diverse menu." says Clark Xie, PhD, Director of Research and Development.

The brand new SignalChem's bioallergen are important research tools to study the diagnostics of allergens and to help IVD manufacturers develop new and more sensitive assays or to optimize existing ones.

 

SignalChem Biotech Inc. is a Canadian company focused on the research, development, and production of innovative and high-quality human recombinant cell signaling products. SignalChem strives to support scientists in academia, pharma, and biotech companies around the world by creating effective research tools to advance the basic research in life sciences and to facilitate the efforts in drug discovery and development.

For more information, please email SignalChem at info@signalchem.com or visit us at www.signalchem.com.

 

CBC News: Biotech coalition hopes llama nanobodies hold key to COVID-19 treatment

August 18, 2020
Continue Reading

CBC News : Read The Full Story Here.

A coalition of Canadian biotech companies are hoping that fragments of antibodies they've raised and sequenced from the blood of a llama immunized to COVID-19 are the key to treating the virus that causes the disease.

After months of research, the Canadian Coalition for COVID-19 says it has published the genetic sequences of 51 of the fragments, called nanobodies, that showed a promising ability to bind to the virus and neutralize it.

Now, they are providing the data to researchers around the world for free in hopes of driving the development of treatments and tests for the coronavirus. The results from the coalition's first tests provide hope for controlling or reducing the severity of the coronavirus in its victims," says Novobind CEO Hamlet Abnousi, who initiated the project.

While most people recover on their own from mild cases of COVID-19, some may require hospitalization and treatment for their symptoms, though according to the B.C. Centre for Disease Control there are still no vaccines or approved medicines for COVID-19.The ambition of the coalition is that other labs and biotech companies can expand on its research by using the sequences to produce the nanobodies in a lab, then testing them to see if one of these nanobodies is the "golden bullet" to prevent the virus from invading human cells and replicating.

Watch the Full Video Here

Nanobodies, or fragments of antibodies found in sharks and camelids (such as camels, alpacas and llamas), have often been used by researchers to study viruses because of their unique attributes.Not only are llama nanobodies roughly one-tenth the size of human antibodies, making them easier to manipulate and better at binding to some viruses, they are nearly 1,000 times cheaper to produce, according to the coalition.

The llama immunized for this project, otherwise known as Maple, lives in Ontario and was given a viral antigen, or COVID-19 spike RBD protein produced in B.C.Maple responded by creating antibodies against the virus, then a local team took a small sample of blood in order to retrieve the antibodies.The blood was sent back to B.C. and scientists were able to isolate the genetic sequences of its nanobodies that bound to the viral antigen.With the sequences identified, the group says laboratories will now be able to inexpensively reproduce the nanobodies on a mass scale.

Hope for the already sick

They can then be screened for therapeutic potential where neutralizing nanobodies can be identified and even enhanced and then used as a preventative measure or treatment for people with COVID-19."I would say the vaccine is the gold standard if we get there, but if you are sick already then you need something to help fight the disease and this is what it would be used for," said Abnousi.

Coalition founder, SignalChem Lifesciences says it has already started to produce the nanobodies at its Richmond, B.C. lab, and will begin performing tests, including with animals to see how effective they are at neutralizing the virus. Research teams seeking access to a licence for the sequences will be asked to sign a pledge committing to the coalition's objective to develop treatments and diagnostics for all people regardless of financial means."Typically labs are very protective of their own proprietary work and so we're hoping to get out there and change the message and say we can share," said Abnousi.

Abnousi is hoping that people or countries with fewer resources to deal with the pandemic can benefit from the project.Vice dean of research at UBC's faculty of medicine, Rob McMaster says the coalition "should be commended for their efforts."With the COVID-19 pandemic there is a real time sensitive need for "Open Science" where results are shared immediately across the world to greatly speed up the development of diagnostics, and to share clinical findings with existing treatments."

Fast-Growing Canadian Life Science Company adopts eTMF Connect to drive greater efficiency and visibility across clinical studies.

Nov 7, 2019
Continue Reading

SignalChem Biotech Inc. has been acknowledged by Inkwood Research as one of the global manufacturers of Biotechnology Reagents. The report details the importance of high-quality biotechnology reagents in pharmaceutical and life science research, and mentions some of the well-established international manufacturers of the life science and analytical reagents. The market report also includes predicted growth in the CAGR for this market in the coming years and other factors affecting this market such as evolving biotechnology landscape and rise in use of proteomic technology for high throughput screening. The full report can be read or accessed by visiting the following site;

 

http://www.rnrmarketresearch.com/global-biotechnology-reagents-market-forecast-2017-2025-market-report.html

 

Life science reagents are extremely important for research and drug discovery projects. The applications for the products in this market segment ranges from basic lab work to DNA/RNA analysis, gene expression, protein synthesis and purification, compound profiling and drug testing. SignalChem and our scientists understand the importance of high-quality life science reagents and we work with only one mission that is to manufacture the best quality reagents for the life science community to expedite their research and drug discovery projects.

 

SignalChem is a Canadian biotech company focused on the research, development, and production of innovative and high-quality human recombinant cell signaling products. SignalChem strives to support scientists in academia, pharma and biotech companies around the world by creating effective research tools to advance the basic research in life sciences and to facilitate the efforts in drug discovery and development. For more information, please contact SignalChem at info@signalchem.com.

SignalChem Initiates Phase 1 Clinical Trial for SLC-391 in Subjects with Solid Tumours

Nov 7, 2019
Continue Reading

VANCOUVER, BRITISH COLUMBIA-(November 7, 2019) - SignalChem Lifesciences Corp. ("SLC"), a clinical stage biotech company, has dosed its first patient in a Phase 1 clinical trial studying the safety and tolerability of SLC-391, a potent and selective AXL inhibitor, at Princess Margaret Cancer Centre in Toronto, Ontario. The study marks a significant clinical milestone for SLC. By taking a targeted therapy approach, the Company aims to develop SLC-391 for the treatment of various forms of cancer.

AXL is a putative driver of diverse cellular processes that are critical for the development, growth, and spread of tumours, including proliferation, invasiveness and migration, epithelial-mesenchymal transition (EMT), stemness, angiogenesis, and immune modulation. It has also been associated with both intrinsic and acquired resistance to chemotherapeutic drugs (e.g, paclitaxel and cisplatin) and molecularly targeted therapies (e.g, erlotinib and gefitinib). AXL has emerged as an increasingly attractive target for anticancer therapies in recent years. SLC-391 is a novel, potent and specific small molecule AXL inhibitor. It has demonstrated antiproliferative activity against different tumour cell lines in vitro and established efficacy in different animal models including non-small cell lung carcinoma (NSCLC), chronic myeloid leukemia (CML) and acute myeloid leukemia (AML) models. It can also work with other approved targeted therapies synergistically in different animal models to potentiate anti-tumour activity.

"Targeting receptor tyrosine kinase AXL represents a promising new approach for treating cancers, especially for cancer metastases, cancer stem cell survival, and acquired resistance to chemotherapies and other targeted therapeutics. SLC has developed its potent, selective and orally bioavailable Axl inhibitor SLC-391 to meet these medical needs. This novel therapy could provide a meaningful and beneficial alternative to cancer patients", commented by Mr. Jun Yan, the CEO and founder of SLC.

About the Phase 1 Trial

The Phase 1 trial is an open-label, dose-escalation, and dose-expansion study of the safety and pharmacokinetics of the AXL Inhibitor SLC-391 administered orally to subjects with solid tumours. The study is being conducted with sites located at The Ottawa Hospital Cancer Centre in Ottawa, Ontario, Princess Margaret Cancer Centre in Toronto, Ontario, and Juravinski Cancer Centre in Hamilton, Ontario. The primary objectives are to evaluate the safety of oral SLC-391 and to determine the maximum tolerated dose (MTD) of SLC-391. The secondary objectives are to characterize the pharmacokinetic (PK) profile of SLC-391, to determine the recommended phase 2 dose (RP2D) of SLC-391 and to preliminarily evaluate the efficacy of SLC-391. For more information about this clinical trial, please visit https://clinicaltrials.gov/ct2/show/NCT03990454.

About SLC-391

SLC-391 is a potent, selective and orally bioavailable small molecule Axl inhibitor. Currently, the phase I clinical trial to evaluate the safety and tolerability of SLC-391 in cancer patients with solid tumour is on-going in Canada.

About SLC

SignalChem Lifesciences Corporation (“SLC�), headquartered in British Columbia, Canada, is a clinical-stage company developing novel targeted therapies for oncology. Its unique business model has been built upon two important pillars: the Bioreagents and Research Services business and the Drug Discovery and Development business. A group of scientists with extraordinary expertise and experience in kinase biology and drug discovery are working together cohesively to provide the best products and services to its customers around the world and to maximize the efficiency of its drug discovery efforts. For more information, please visit www.signalchemlifesciences.com.

Forward-Looking Statements and Information

This release contains forward-looking statements that are not based on historical facts. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied. Readers are cautioned not to place undue reliance on such forward-looking statements.

Contact:
Zaihui Zhang, PhD
CSO, VP R & D
Signalchem Lifesciences Corp.
+ 604 232 4600 ext. 114

SignalChem Adopts eTMF Connect to Enhance Clinical Programs & Better Serve Customers

Nov 5, 2019

Fast-Growing Canadian Life Science Company adopts eTMF Connect to drive greater efficiency and visibility across clinical studies.

Continue Reading

MONTREAL and RICHMOND, CA - Nov 5, 2019 - Montrium, a global leader in cloud-based software solutions for the life sciences, today announced that SignalChem has successfully implemented their eTMF Connect application to improve clinical operations in drug development for their oncology-related programs. SignalChem now benefits from a robust and powerful electronic Trial Master File solution with eTMF Connect, streamlining the management of clinical trial content between study teams, providing them with a centralized interface for effective collaboration.

Performing drug discovery and development to treat different types of cancers, SignalChem has seen significant growth in targeted therapies in recent years.SignalChem’slatest clinical program, the protein kinase AXL Inhibitor SLC-391 for cancer therapy, is set to act as a critical inhibitor for cancer cell growth and metastasis. AXL is believed to play key roles in cancer cell survival, angiogenesis, metastasis and therapeutic resistance, as well as anti-tumour immunity suppression.

SignalChem’s transition to a modern eTMF system allows for better oversight with a more dedicated collaborative environment for partners to connect through one platform resulting in the delivery of safer treatments to patients faster. “eTMF Connect allows for easy, direct access to critical TMF content and data. We can ensure that our clinical studies and their respective TMFs are managed with greater quality, visibility and efficiency to scale research efforts and continue growth,� said Dr. Zaihui Zhang, CSO and VP of R&D

Montrium was able to both deliver and support the rapid implementation of the eTMF Connect software, allowing the SignalChem teams to realize the benefits of an eTMF system far faster than initially expected.

“As a clinical-stage company with an ambitious pipeline, we need a leading technology platform to streamline our clinical operations,� said Dr. Zhang. “Montrium’s eTMF Connect application helps our study teams work efficiently remotely and gives our program leaders better visibility into trial master file quality, timeliness and completeness. From the first engagement with Montrium, it was clear they wanted to nurture a lasting partnership, and their attention to detail was obvious from the start.�

“We are thrilled to be working with SignalChem, a fellow Canadian company, and to help them empower their continued success in oncology research and development. This partnership attests to the positive impact cloud-based platforms have in the life sciences industry,� said Oliver Pearce, Director of Commercialization at Montrium.

Additional Information

•  For more information, please visit: www.montrium.com and www.signalchemlifesciences.com
•  To learn more about how eTMF Connect can improve your clinical trial operations, please visit www.montrium.com/etmf-connect
•  Connect with Montrium and SignalChem on LinkedIn

About Montrium

Founded in 2005, Montrium is one of the leading providers of cloud-based collaborative content management software to the life sciences industry. With experience in serving over 200 life science customers in 20+ countries, Montrium is committed to delivering an unparalleled customer experience to emerging growth organizations as a true technology partner. Montrium is headquartered in Montreal, Canada, with a European office in Brussels, Belgium.

About SignalChem

SignalChem Lifesciences Corporation (“SLC�), headquartered in British Columbia, Canada, is a clinical-stage company developing novel targeted therapies for oncology. Its unique business model has been built upon two important pillars: the Bioreagents and Research Services business and the Drug Discovery and Development business. A group of scientists with extraordinary expertise and experience in kinase biology and drug discovery are working together cohesively to provide the best products and services to its customers around the world and to maximize the efficiency of its drug discovery efforts.

Contact:
Madison Ramsay
Marketing Operations Lead, Montrium
+1 514 223 9153 ext. 218

Zaihui Zhang, PhD
CSO, VP R & D
Signalchem Lifesciences Corp.
+ 604 232 4600 ext. 114

Signalchem Biotech Inc. and Innophore announces a new partnership

Nov 1, 2019

Fast-Growing Canadian Life Science Company adopts eTMF Connect to drive greater efficiency and visibility across clinical studies.

Continue Reading

RICHMOND, CA - Nov 1, 2019 - Signalchem Biotech Inc. and Innophore have initiated a new strategic partnership. Both companies have agreed to collaborate their expertise in the field of recombinant protein engineering, bioinformatics, and artificial intelligence to provide better solutions for Drug & Enzyme discovery projects. Signalchem is a leading manufacturer of recombinant proteins such as Kinases and Ubiquitins, and these enzymes have been thoroughly studied in multiple human diseases such as cancer and neurodegeneration.

Using Innophore’s cutting edge technology as their Catalophore platform, it will make it possible for the life science researchers and clinicians to expedite their understanding of these enzymes using these kinase data sets provided by Signalchem. New insights gained with the help of these artificial intelligent machineries promises to transform the drug discovery process in the near future. Signalchem and Innophore are excited to be a part of this transformation, which will take us a step closer towards curing multiple diseases.

SignalChem is a Canadian biotech company focused on the research, development, and production of innovative and high-quality human recombinant cell signaling products. SignalChem strives to support scientists in academia, pharma and biotech companies around the world by creating effective research tools to advance the basic research in life sciences and to facilitate the efforts in drug discovery and development. For more information, please contact signalchem at info@signalchem.com.

SignalChem Lifesciences Corp. to Present Data on the Role of its AXL Inhibitor SLC-391 in Promoting Anti-Tumor Activity

April 9, 2018

•  AXL expression is up-regulated by transformed cells and the tumor microenvironment;
•  Up-regulation of AXL elicits an anti-inflammatory effect;
•  SLC-391 mediates a pro-inflammatory response by promoting a M2 to M1 transition; and
•  SLC-391 inhibits M2-induced epithelial mesenchymal transition (EMT).

Continue Reading

VANCOUVER, BRITISH COLUMBIA – April 9, 2018 – SignalChem Lifesciences Corporation (“SLC�) announced that it will present a poster detailing the preclinical data for its AXL inhibitor, SLC-391 at the AACR Annual Meeting, being held from April 14-18, 2018 in Chicago, IL.

Details of the poster to be presented are as follows:
Title: AXL inhibitor promotes anti-tumor immunity through modulation of macrophage polarization
Section: PO.ETO6.11 – Novel and Canonical Targets
Poster Session: Section 35
Date and Time: Tuesday, April 17; 8:00 AM – 12:00 PM
Presenter: Shenshen Lai, PhD. SignalChem Lifesciences Corporation

About SLC-391

SLC-391 is a selective small molecule inhibitor of AXL and other TAM family kinases (Tyro3 and Mer). Currently, IND-enabling GLP-toxicological studies are underway and are expected to be completed in Q3 2018. With favorable results, SignalChem plans to initiate Phase I clinical trials in Q4 2018.

About SLC

SLC is a privately held and clinical stage biotechnology company specializing in enabling personalized medicine strategies to improve human health. The company offers bio-reagents (tools and services used for research purposes) to organizations worldwide and leverages the internally developed enzyme technology platform to discover inhibitors of the untapped targets with a view of advancing these therapeutic programs into early clinical development stages. SLC’s current therapeutic development programs are related to hypoxia (cancer), specifically CAIX which is involved in mediating metastasis and AXL tyrosine kinase is involved in perpetuating resistance to standard chemo- and radiation therapy. SLC has established a strategic corporate alliance with Welichem Biotech Inc. to support the clinical development of its first program SLC-0111, a CAIX inhibitor for the treatment of metastatic cancer. A Phase 1B study evaluating SLC-0111 with gemcitabine in pancreatic cancer is expected to commence in Q2 2018. GLP toxicological studies for SLC’s second program, Axl inhibitor SLC-391, are currently underway with results to be expected in Q3 2018. SLC is actively seeking opportunities for a co-development partnership for the AXL program.

Forward-Looking Statements and Information

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.

The Terry Fox Laboratory and SignalChem Lifesciences to Present Data on the AXL Inhibitor SLC-0211 (SLC-391) at the 59th ASH Annual Meeting & Exposition

Dec. 8, 2017

•  Activation of the GAS6/AXL pathway plays a major role in the resistance to targeted therapies and conventional cytotoxic drugs;
•  Cells with high GAS6/AXL expression were more sensitive to SLC-0211 (SLC-391) than those with low GAS6 and/or AXL levels;
•  SLC-0211 (SLC-391) reduced colony forming cell (CFC) ability of CD34+ AML cells, but the inhibitory effect of SLC-0211 (SLC-391) was strikingly enhanced in re-plating assays, resulting in a significant reduction in re-plating efficiency of more primitive AML cells (75-97% inhibition) at doses that are not toxic to healthy cells;
•  Treatment with SLC-0211 (SLC-391) greatly reduced phosphorylation of AXLY779, AKTS473 and ERKT202/Y204 in AML cells in a dose-dependent manner as compared to control cells;
•  Targeting AXL is a promising strategy for AML cases characterized by populations of CD34+ cells that harbor specific mutations, coupled with elevated AXL/GAS6 activity.

Continue Reading

VANCOUVER, BRITISH COLUMBIA – Dec. 8, 2017 – SignalChem Lifesciences Corporation (“SLC�) announced that it will present a poster detailing the preclinical data for its AXL inhibitor, SLC-0211 (SLC-391) at the 59th ASH Annual Meeting & Exposition, being held from December 9 – 12, 2017 in Atlanta, Georgia.

Details of the poster to be presented are as follows:
Title: Targeting the GAS6/AXL Pathway with a Newly Developed, Selective AXL Inhibitor SLC-0211 in Acute Myeloid Leukemia Mutant Cells
Abstract Number: 616
Poster Session: Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II
Date and Time: Sunday, December 10; 6:00 PM - 8:00 PM
Presenter: Xiaojia Niu. Terry Fox Laboratory, British Columbia Cancer Agency; Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada; National Engineering Laboratory for AIDS Vaccine, Key Laboratory for Molecular Enzymology and Engineering, the Ministry of Education, School of Life Sciences, Jilin University, Changchun, P. R. China

About SLC-0211 (SLC-391)

SLC-0211 (SLC-391) is a selective small molecule inhibitor of AXL and other TAM family kinases (Tyro3 and Mer). Currently, IND-enabling GLP-toxicological studies are underway and are expected to be completed in Q4 2017. With favorable results, SignalChem plans to initiate Phase I clinical trials in Q3 2018.

About SLC

SLC is a privately held and clinical stage biotechnology company specializing in enabling personalized medicine strategies to improve human health. The company offers bio-reagents (tools and services used for research purposes) to organizations worldwide and leverages the internally developed enzyme technology platform to discover inhibitors of the untapped targets with a view of advancing these therapeutic programs into early clinical development stages. SLC’s current therapeutic development programs are related to hypoxia (cancer), specifically CAIX which is involved in mediating metastasis and AXL tyrosine kinase is involved in perpetuating resistance to standard chemo- and radiation therapy. SLC has established a strategic corporate alliance with Welichem Biotech Inc. to support the clinical development of its first program SLC-0111, a CAIX inhibitor for the treatment of metastatic cancer. A Phase 1B study evaluating SLC-0111 with gemcitabine in pancreatic cancer is expected to commence in Q1 2018. GLP toxicological studies for SLC’s second program, Axl inhibitor SLC-391, are currently underway with results to be expected in Q4, 2017. SLC is actively seeking opportunities for a co-development partnership for the AXL program.

Forward-Looking Statements and Information

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.

SignalChem Lifesciences to Present Data on the AXL Inhibitor SLC-391 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer

Oct. 25, 2017

•  SLC-391 inhibits CT-26 tumor growth by 37% in a 15-day efficacy study whereas PD-1 antibody delayed tumor growth by 27%;
•  Increases in the number of NK cells and the ratio of M1/M2-polarized macrophages were evident in the SLC-391 treatment group when compared to vehicle;
•  In combination with anti-PD1, SLC-391 significantly prolongs survival, reinforcing the implication of AXL inhibition in immuno-oncology.

Continue Reading

VANCOUVER, BRITISH COLUMBIA – Oct. 25, 2017 – SignalChem Lifesciences Corporation (“SLC�) announced that it will present a poster detailing the preclinical data for its AXL inhibitor, SLC-391 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held from October 26 – 30, 2017 in Philadelphia, Pennsylvania.

Details of the poster to be presented are as follows:
Title: Activity of the TAM kinase-targeting compound, SLC-391, is mediated by the engagement of the immune system in CT-26 syngeneic mouse model
Abstract Number: 522
Poster Session: PO.B10 – New Molecular Targets
Date and Time: Sunday, October 29; 12:30 – 4:00 PM
Presenter: Anthony Marotta, PhD. SignalChem Lifesciences Corporation

About SLC-391

SLC-391 is a selective small molecule inhibitor of AXL and other TAM family kinases (Tyro3 and Mer). Currently, IND-enabling GLP-toxicological studies are underway and are expected to be completed in Q4 2017. With favorable results, SignalChem plans to initiate Phase I clinical trials in Q3 2018.

About SLC

SLC is a privately held and clinical stage biotechnology company specializing in enabling personalized medicine strategies to improve human health. The company offers bio-reagents (tools and services used for research purposes) to organizations worldwide and leverages the internally developed enzyme technology platform to discover inhibitors of the untapped targets with a view of advancing these therapeutic programs into early clinical development stages. SLC’s current therapeutic development programs are related to hypoxia (cancer), specifically CAIX which is involved in mediating metastasis and AXL tyrosine kinase is involved in perpetuating resistance to standard chemo- and radiation therapy. SLC has established a strategic corporate alliance with Welichem Biotech Inc. to support the clinical development of its first program SLC-0111, a CAIX inhibitor for the treatment of metastatic cancer. A Phase 1B study evaluating SLC-0111 with gemcitabine in pancreatic cancer is expected to commence in Q1 2018. GLP toxicological studies for SLC’s second program, Axl inhibitor SLC-391, are currently underway with results to be expected in Q4, 2017. SLC is actively seeking opportunities for a co-development partnership for the AXL program.

Forward-Looking Statements and Information

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.

SignalChem Initiates Phase 1 Clinical Trial for SLC-0111 in Solid Tumours

Dec 4, 2014

SignalChem Lifesciences Corp. ("SLC"), has dosed its first patient in a Phase 1a clinical trial studying the safety and tolerability of SLC-0111. The study marks a significant clinical milestone for SLC. Taking a personalized medicine approach, the Company is developing SLC-0111 for the targeted treatment of various forms of cancer.

Continue Reading

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Dec 4, 2014) - SignalChem Lifesciences Corp. ("SLC"), has dosed its first patient in a Phase 1a clinical trial studying the safety and tolerability of SLC-0111. The study marks a significant clinical milestone for SLC. Taking a personalized medicine approach, the Company is developing SLC-0111 for the targeted treatment of various forms of cancer. SLC-0111 is a proprietary small molecule that selectively targets CAIX enzyme within the hypoxic regions of the tumour. Hypoxic areas of tumours host aggressive cancer cells that are resistant to conventional therapies and CAIX plays a critical role in their survival. No drug therapies currently exist for blocking CAIX enzyme activity in hypoxic areas of solid tumours. "There is currently a significant unmet need for a treatment that could decrease the survival of cancer cells in the hypoxic regions of a tumour, said Jasbinder Sanghera, PhD., CEO of SLC. "Targeting the CAIX enzyme represents a promising new approach for treating and preventing tumour growth, especially recurrence, and SLC is the first company that has demonstrated success in reaching these difficult areas of the tumour. This therapy could provide a meaningful benefit to cancer patients." The initiation of clinical development for SLC-0111 follows extensive research and preclinical studies where the compound demonstrated consistently positive effects for the treatment of various tumours. "Our studies have demonstrated that SLC-0111 may work well in effectively stopping and shrinking various tumours, prevent recurrence, metastases, and cancer stem cell survival, commented Dr. Shoukat Dedhar, one of the original developers of the program, distinguished scientist and the Professor of the Department of Integrative Oncology, BC Cancer Research Centre and University of British Columbia. "This program may prove to be a major step forward in treating both tumour growth and spread in a segment of the tumour, which if left untreated, has a devastating impact on patients." SLC is also developing a backup small molecule inhibitor of CAIX (SLC-021) and in collaboration with the National Research Council of Canada, a monoclonal antibody (SLC-0131) targeting CAIX. Both programs are in the preclinical development stage.

About the Phase 1 Trial

The Phase 1a trial is a dose escalation study and the Company will enroll up to 30 cancer patients with refractory solid tumours. The study is being conducted by Ozmosis Research Inc., Toronto, ON with sites located at The Princess Margaret in Toronto, Ontario, the Cross Cancer Institute in Edmonton, Alberta and the BC Cancer Agency in Vancouver, BC. The primary objective is to investigate the safety and tolerability of SLC-0111. The company plans to start Phase 1b studies later in 2015. These trials will involve selecting patients whose tumours express CAIX and treating only these patients with SLC-0111.

About CAIX

SLC has identified and validated the metalloenzyme Carbonic Anhydrase IX (CAIX), which is expressed selectively on the cell surface of hypoxic (oxygen depleted) tumour cells particularly cancer stem cells, and is one of the major factors contributing to cancer cell survival and metastasis. The role of CAIX is to catalyse the reversible hydration of carbon dioxide to bicarbonate and protons: H2O + CO2 to HCO3- + H+.

About SLC

SignalChem Lifesciences ("SLC") discovers and develops drug candidates using a personalized medicine approach. We identify patients with a specific kinase defect and then select a relevant targeted therapy against the defective kinase. SLC's development process selects the most relevant kinase targets for drug development and identifies the best compound from our kinase specific chemical library. This ensures best-in-class potency and superior selectivity; yielding highly effective drug candidates with greatly reduced side effects. Our approach has the potential to provide a much more effective therapy and allows SLC to apply the therapy to only those patients who are most likely to receive a meaningful clinical benefit. For more information please visit www.signalchemcorp.com.

Forward-Looking Statements and Information

This release contains forward-looking statements that are not based on historical facts. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied. Readers are cautioned not to place undue reliance on such forward-looking statements.